Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the overall patient population. Selinexor is an inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Nina, Chaudhry, Sana, Totiger, Tulasigeri M., Diaz, Robert, Roberts, Evan, Montoya, Skye, Pardo, Gabriel, Pardo, Alejandro, Afaghani, Jumana, Affer, Maurizio, Jahn, Jacob, Bradley, Terrence, Maura, Francesco, Kazandjian, Dickran, Bilbao, Daniel, Chapman, Jennifer, Landgren, Ola, Hoffman, James, Taylor, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581939/
https://www.ncbi.nlm.nih.gov/pubmed/36261486
http://dx.doi.org/10.1038/s41698-022-00315-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581939/
https://www.ncbi.nlm.nih.gov/pubmed/36261486
http://dx.doi.org/10.1038/s41698-022-00315-2

Ejemplares similares